NCT02099864View on ClinicalTrials.gov

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 5, 2014

Primary Completion Date

October 1, 2019

Study Completion Date

July 8, 2024

Conditions

Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Soft TissuesMetastatic Prostate AdenocarcinomaRecurrent Prostate CarcinomaStage III Prostate Adenocarcinoma AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7

Interventions

DRUG

Enzalutamide

Given PO

Trial Locations (2)

94115

UCSF Medical Center-Mount Zion, San Francisco

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors

collaborator

Astellas Pharma US, Inc.

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER

NCT02099864 - Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy | Biotech Hunter | Biotech Hunter